CytomX Therapeutics (CTMX) Competitors $0.85 -0.02 (-2.05%) (As of 10:21 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CTMX vs. DRRX, MEIP, SELB, URGN, ETON, PSTX, ATAI, ATYR, FATE, and BNTCShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include DURECT (DRRX), MEI Pharma (MEIP), Selecta Biosciences (SELB), UroGen Pharma (URGN), Eton Pharmaceuticals (ETON), Poseida Therapeutics (PSTX), Atai Life Sciences (ATAI), Atyr PHARMA (ATYR), Fate Therapeutics (FATE), and Benitec Biopharma (BNTC). These companies are all part of the "medical" sector. CytomX Therapeutics vs. DURECT MEI Pharma Selecta Biosciences UroGen Pharma Eton Pharmaceuticals Poseida Therapeutics Atai Life Sciences Atyr PHARMA Fate Therapeutics Benitec Biopharma CytomX Therapeutics (NASDAQ:CTMX) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation. Do analysts rate CTMX or DRRX? CytomX Therapeutics presently has a consensus price target of $5.77, suggesting a potential upside of 563.43%. DURECT has a consensus price target of $5.00, suggesting a potential upside of 453.34%. Given CytomX Therapeutics' higher possible upside, research analysts plainly believe CytomX Therapeutics is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50DURECT 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer CTMX or DRRX? CytomX Therapeutics received 56 more outperform votes than DURECT when rated by MarketBeat users. Likewise, 65.49% of users gave CytomX Therapeutics an outperform vote while only 63.84% of users gave DURECT an outperform vote. CompanyUnderperformOutperformCytomX TherapeuticsOutperform Votes37265.49% Underperform Votes19634.51% DURECTOutperform Votes31663.84% Underperform Votes17936.16% Do institutionals and insiders believe in CTMX or DRRX? 67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 7.0% of CytomX Therapeutics shares are owned by insiders. Comparatively, 3.2% of DURECT shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, CTMX or DRRX? CytomX Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, DURECT has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Does the media refer more to CTMX or DRRX? In the previous week, DURECT had 8 more articles in the media than CytomX Therapeutics. MarketBeat recorded 11 mentions for DURECT and 3 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.70 beat DURECT's score of 0.20 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DURECT 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CTMX or DRRX more profitable? CytomX Therapeutics has a net margin of 10.96% compared to DURECT's net margin of -198.58%. CytomX Therapeutics' return on equity of -41.47% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics10.96% -41.47% 8.11% DURECT -198.58%-300.62%-65.17% Which has higher valuation & earnings, CTMX or DRRX? CytomX Therapeutics has higher revenue and earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$101.21M0.67-$570K$0.175.12DURECT$8.55M3.28-$27.62M-$0.61-1.48 SummaryCytomX Therapeutics beats DURECT on 14 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.09M$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio5.1210.78126.3117.81Price / Sales0.67243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book-1.235.474.684.68Net Income-$570,000.00$153.61M$119.54M$226.08M7 Day Performance-12.99%-2.00%-1.83%-1.04%1 Month Performance-24.99%-7.46%-3.60%1.04%1 Year Performance-33.33%31.82%31.91%26.28% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.3829 of 5 stars$0.85-2.0%$5.77+577.3%-37.4%$66.70M$101.21M5.01170Short Interest ↓DRRXDURECT3.0843 of 5 stars$0.87-3.6%$5.00+474.1%+39.5%$27.03M$8.55M0.0080Analyst ForecastAnalyst RevisionNews CoverageMEIPMEI Pharma4.1926 of 5 stars$2.78-0.7%$7.00+151.8%-50.5%$18.52M$65.30M-0.40100SELBSelecta BiosciencesN/AN/AN/AN/A$136.76M$110.78M-4.0164Gap DownHigh Trading VolumeURGNUroGen Pharma3.7235 of 5 stars$11.36-0.8%$48.38+325.8%-7.9%$266.39M$82.71M-3.63200ETONEton Pharmaceuticals2.9126 of 5 stars$10.30-1.2%$13.00+26.2%+202.8%$266.15M$31.64M0.0020Short Interest ↓Analyst RevisionPSTXPoseida Therapeutics4.0406 of 5 stars$2.70-0.7%$15.00+455.6%-0.5%$263.14M$64.70M0.00260ATAIAtai Life Sciences2.3842 of 5 stars$1.55-2.7%$9.00+481.5%+42.0%$259.70M$310,000.000.0083Analyst ForecastAnalyst RevisionATYRAtyr PHARMA2.8572 of 5 stars$2.95-1.3%$19.25+552.5%N/A$247.62M$350,000.00-3.1856FATEFate Therapeutics3.9234 of 5 stars$2.16-2.7%$6.75+212.5%-14.6%$246.00M$63.53M0.00550Analyst UpgradeNews CoverageBNTCBenitec Biopharma2.2984 of 5 stars$10.49-1.6%$22.60+115.4%+202.8%$243.58M$80,000.000.0020Positive News Related Companies and Tools Related Companies DURECT Competitors MEI Pharma Competitors Selecta Biosciences Competitors UroGen Pharma Competitors Eton Pharmaceuticals Competitors Poseida Therapeutics Competitors Atai Life Sciences Competitors Atyr PHARMA Competitors Fate Therapeutics Competitors Benitec Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTMX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTMX Stock Alerts